Diabetes News February 11th 2011

Clinical Significance of Urinary Liver-Type Fatty Acid Binding Protein in Diabetic Nephropathy of Type 2 Diabetic Patient
Urinary L-FABP accurately reflected the severity of diabetic nephropathy in type 2 diabetes, and its level was high in the patients with normoalbuminuria. Moreover, higher urinary L-FABP was a risk factor for progression of diabetic nephropathy (Diabetes Care)

Proteinuria in Type 2 Diabetic Patients with Renal Impairment: The Changing Face of Diabetic Nephropathy
We suggest that the high prevalence of ACEi and ARB usage in patients with type 2 DN may be effecting the traditional clinical paradigm of type 2 DN – abstract (Nephron Clinical Practice)

Effect of linagliptin monotherapy on glycaemic control and markers of ß-cell function in patients with inadequately controlled type 2 diabetes
Monotherapy with linagliptin produced a significant, clinically meaningful and sustained improvement in glycaemic control, accompanied by enhanced parameters of ß-cell function. The safety profile of linagliptin was comparable with that of placebo (Diabetes, Obesity and Metabolism)

Enterovirus infection and type 1 diabetes mellitus: systematic review and meta-analysis of observational molecular studies
There is a clinically significant association between enterovirus infection, detected with molecular methods, and autoimmunity/type 1 diabetes (BMJ)

Proposals to amend driving licence standards for vision, diabetes and epilepsy
The consultation runs for 12 weeks from 03/02/2011 until 28/04/2011 (Driver and Vehicle Licensing Agency)

European Proposals to amend Driving Licence Standards for Diabetes
This Impact Assessment (IA) forms part of a full public consultation process carried out in accordance with the „Code of Practice on Consultations? issued by the Cabinet Office (Department for Transport and DVLA)

GPs offered diabetes research training
A diabetes research training scheme for GPs has been launched as part of a joint venture between Diabetes UK and the Royal College of General Practitioners (Management in Practice)

No Loss of Chance of Diabetic Retinopathy Screening by Endocrinologists With a Digital Fundus Camera
The endocrinologist with specific training for DR detection using a three-field digital fundus camera with pupillary dilatation can perform a reliable DR screening without any loss of chance for the patients when compared with identical evaluation performed by experienced ophthalmologists (Diabetes Care)

Strategies to Improve Medication Adherence Reported by Diabetes Patients and Caregivers
Results of a Taking Control of Your Diabetes Survey (Annals of Pharmacotherapy)

Heart failure therapy in diabetic patients
Comparison with the recent ESC/EASD guideline (Cardiovascular Diabetology)

Dietary Guidelines for Americans
The Dietary Guidelines for Americans has been published jointly every 5 years since 1980 by the Department of Health and Human Services (HHS) and the Department of Agriculture (USDA)

Impact of Depression on Health Related Quality of Life in Patients with Diabetes
By far the most signifi cant negative impact on all the domains of HRQOL was due to the presence of depressive symptom (Annals, Academy of Medicine, Singapore)

Antidiabetic Properties of the Histamine H3 Receptor Protean Agonist Proxyfan
These findings demonstrate, for the first time, that manipulation of central histamine H3 receptor by proxyfan can significantly improve glucose excursion by increasing plasma insulin levels via a glucose-independent mechanism (Endocrinology)

Avandia (rosiglitazone) labels now contain updated information about cardiovascular risks and use in certain patients
The U.S. Food and Drug Administration (FDA) is notifying the public that information on the cardiovascular risks (including heart attack) of the diabetes drug rosiglitazone has been added to the physician labeling and patient Medication Guid (FDA)

Takeda Enrolls Clinical Trial Subject in Phase 3 Study of Alogliptin in China
Alogliptin is a dipeptidyl peptidase-IV (DPP-4) inhibitor and was created by Takeda San Diego, Inc., Takeda’s wholly-owned subsidiary located in San Diego, California. It has already been launched as “NESINA®” in Japan, and is currently under development for other regions (Takeda)

Targacept Announces Initiation of Phase 2 Studies of TC-6987 in Asthma and Type 2 Diabetes
TC-6987 demonstrated a potent anti-inflammatory response in a variety of preclinical studies conducted by Targacept, including models of asthma and diabetes, and was generally well tolerated in Phase 1 clinical trials (Targacept)